Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontunisertib in Fibrostenosing Crohn's Disease
NCT07683325Phase 2Recruiting
- Sponsor
- Agomab Therapeutics
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of ontunisertib in Crohn's disease (4 arms), sponsored by Agomab Therapeutics. Primary endpoint: Proportion of participants achieving endoscopic passability of the ileal index stricture at 24 weeks. Started Oct 2026; status: recruiting.
02
Drugs
ontunisertib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07683325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683325.